Phibro Animal Health Corporation (PAHC) to Issue Quarterly Dividend of $0.12 on March 25th

Phibro Animal Health Corporation (NASDAQ:PAHC) announced a quarterly dividend on Tuesday, February 3rd. Stockholders of record on Wednesday, March 4th will be given a dividend of 0.12 per share on Wednesday, March 25th. This represents a c) annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, March 4th.

Phibro Animal Health has a dividend payout ratio of 23.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Phibro Animal Health to earn $2.10 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 22.9%.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $41.00 on Thursday. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. The firm has a 50-day moving average of $39.74 and a 200-day moving average of $38.06. Phibro Animal Health has a one year low of $16.16 and a one year high of $46.42. The company has a market cap of $1.66 billion, a P/E ratio of 24.70, a P/E/G ratio of 1.17 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts forecast that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.